Telo Genomics Advances Blood-Based MRD Validation in Myeloma
Toronto, Ontario, December 18, 2025 — Telo Genomics Corp. has initiated a new retrospective blood-based minimal residual disease (MRD)...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Toronto, Ontario, December 18, 2025 — Telo Genomics Corp. has initiated a new retrospective blood-based minimal residual disease (MRD)...
TORONTO, Ontario — November 13, 2025: Telo Genomics announced it will present its groundbreaking individual-cell MRD risk-assessment technology at...
